Search Results - "Irvin, David M."

Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model by Okolie, Onyinyechukwu, Bago, Juli R, Schmid, Ralf S, Irvin, David M, Bash, Ryan E, Miller, C Ryan, Hingtgen, Shawn D

“…Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenvironment due to limited preclinical models…”
Get full text

Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models by Irvin, David M., McNeill, Robert S., Bash, Ryan E., Miller, C. Ryan

“…The influence of cellular origin on glioma pathogenesis remains elusive. We previously showed that mutations inactivating Rb and Pten and activating Kras…”
Get full text

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas by Hariharan, Seethalakshmi, Whitfield, Benjamin T., Pirozzi, Christopher J., Waitkus, Matthew S., Brown, Michael C., Bowie, Michelle L., Irvin, David M., Roso, Kristen, Fuller, Rebecca, Hostettler, Janell, Dharmaiah, Sharvari, Gibson, Emiley A., Briley, Aaron, Mangoli, Avani, Fraley, Casey, Shobande, Mariah, Stevenson, Kevin, Zhang, Gao, Malgulwar, Prit Benny, Roberts, Hannah, Roskoski, Martin, Spasojevic, Ivan, Keir, Stephen T., He, Yiping, Castro, Maria G., Huse, Jason T., Ashley, David M.

“…Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX , defining…”
Get full text

Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection by Okolie, Onyinyechukwu, Irvin, David M, Bago, Juli R, Sheets, Kevin, Satterlee, Andrew, Carey-Ewend, Abigail G, Lettry, Vivien, Dumitru, Raluca, Elton, Scott, Ewend, Matthew G, Miller, C Ryan, Hingtgen, Shawn D

“…Cytotoxic neural stem cells (NSCs) have emerged as a promising treatment for Medulloblastoma (MB), the most common malignant primary pediatric brain tumor. The…”
Get full text

Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma by Vitucci, Mark, Irvin, David M, McNeill, Robert S, Schmid, Ralf S, Simon, Jeremy M, Dhruv, Harshil D, Siegel, Marni B, Werneke, Andrea M, Bash, Ryan E, Kim, Seungchan, Berens, Michael E, Miller, C Ryan

“…Gliomas are diverse neoplasms with multiple molecular subtypes. How tumor-initiating mutations relate to molecular subtypes as these tumors evolve during…”
Get full text

Vascular channels formed by subpopulations of PECAM1+ melanoma cells by Dunleavey, James M., Xiao, Lin, Thompson, Joshua, Kim, Mi Mi, Shields, Janiel M., Shelton, Sarah E., Irvin, David M., Brings, Victoria E., Ollila, David W., Brekken, Rolf A., Dayton, Paul A., Melero-Martin, Juan M., Dudley, Andrew C.

Get full text

MerTK as a therapeutic target in glioblastoma by Wu, Jing, Frady, Lauren N, Bash, Ryan E, Cohen, Stephanie M, Schorzman, Allison N, Su, Yu-Ting, Irvin, David M, Zamboni, William C, Wang, Xiaodong, Frye, Stephen V, Ewend, Matthew G, Sulman, Erik P, Gilbert, Mark R, Earp, H Shelton, Miller, C Ryan

“…Glioma-associated macrophages and microglia (GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase…”
Get full text

BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea–Induced Gliomagenesis by McNeill, Robert S, Irvin, David M, Miller, C. Ryan

“…This commentary highlights the article by Wang et al that describes a preclinical model for targeting BRAF-mutant gliomas…”
Get full text

Vascular channels formed by subpopulations of PECAM1+ melanoma cells by Dunleavey, James M., Xiao, Lin, Thompson, Joshua, Kim, Mi Mi, Shields, Janiel M., Shelton, Sarah E., Irvin, David M., Brings, Victoria E., Ollila, David W., Brekken, Rolf A., Dayton, Paul A., Melero-Martin, Juan M., Dudley, Andrew C.

“…Targeting the vasculature remains a promising approach for treating solid tumours; however, the mechanisms of tumour neovascularization are diverse and…”
Get full text

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma by McNeill, Robert S, Canoutas, Demitra A, Stuhlmiller, Timothy J, Dhruv, Harshil D, Irvin, David M, Bash, Ryan E, Angus, Steven P, Herring, Laura E, Simon, Jeremy M, Skinner, Kasey R, Limas, Juanita C, Chen, Xin, Schmid, Ralf S, Siegel, Marni B, Van Swearingen, Amanda E D, Hadler, Michael J, Sulman, Erik P, Sarkaria, Jann N, Anders, Carey K, Graves, Lee M, Berens, Michael E, Johnson, Gary L, Miller, C Ryan

“…Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments…”
Get full text